Integrated BioPharma Inc (INBP) q3 2025 Earnings Report

Executive Summary

Integrated BioPharma Inc (INBP) reported QQ3 2025 results with a modest top-line expansion and meaningful improvement in profitability and cash generation despite a small-scale operation. Revenue totaled $13.95 million, up 6.09% year-over-year and 10.57% quarter-over-quarter, while gross profit reached $1.55 million for a gross margin of 11.12%. EBITDA stood at $1.043 million and operating income at $0.739 million, yielding an operating margin of 5.30% and a net income of $0.611 million (EPS: $0.02). The quarter benefited from favorable cost control and mix shift, helping EBITDA and net income expand meaningfully versus prior periods (YoY EBITDA margin 7.48%; net income margin 4.38%).

Key Performance Indicators

Revenue

13.95M

QoQ: 10.57% | YoY:6.09%

Gross Profit

1.55M

11.12% margin

QoQ: 32.45% | YoY:24.28%

Operating Income

739.00K

QoQ: 265.84% | YoY:108.17%

Net Income

611.00K

QoQ: 426.72% | YoY:114.39%

EPS

0.02

QoQ: 426.32% | YoY:110.53%

Revenue Trend

Margin Analysis

Key Insights

Financial Highlights

Revenue: $13.95M; YoY +6.09%; QoQ +10.57%
Gross Profit: $1.551M; Gross Margin 11.12%; YoY Gross Profit growth +24.28%; QoQ +32.45%
Operating Income: $0.739M; Margin 5.30%; YoY +108.17%; QoQ +265.84%
Net Income: $0.611M; Margin 4.38%; YoY +114.39%; QoQ +426.72%
EPS: $0.02 basic/diluted; YoY +110.53%; QoQ +426.32%
EBITDA: $1.043M; EBITDA Margin 7.48%
Cash Flow: Operating cash flow $0.616M; Capex $0.116M; Free cash flow $0.500M; Net change in cash +$0.50M; Cash at period end $2.961M
Liquidity & Balance Sheet: Current ratio 3.72; Quick ratio 1.70; Cash ratio 0.59; Inventory $10.077M; Net receivables $5.08M; Total assets $25.656M; Total liabilities $5.273M; Total equity $20.383M; Retained earnings negative at $(31.241)M; Net debt position is negative $(1.825)M (cash greater than debt).
Valuation: Price/Earnings ~4.22x; Price/Book ~0.51x; EV/ EBITDA ~11.5x; Price/FCF ~20.6x.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	13.95M	6.09%	10.57%
Gross Profit	1.55M	24.28%	32.45%
Operating Income	739.00K	108.17%	265.84%
Net Income	611.00K	114.39%	426.72%
EPS	0.02	110.53%	426.32%

Key Financial Ratios

currentRatio

3.72

returnOnAssets

2.38%

returnOnEquity

debtEquityRatio

0.06

operatingCashFlowPerShare

$0.02

freeCashFlowPerShare

$0.02

priceToBookRatio

0.51

priceEarningsRatio

4.22

Net Income vs. Revenue

Expense Breakdown

Competitive Position

Company	Gross Margin	Operating Margin	Return on Equity	P/E Ratio
INBP Focus	11.12%	0.00%	3.00%	4.22%
PRRFY	38.30%	17.00%	2.63%	42.77%
TQLB	1.00%	15.10%	68.80%	212.13%
NSPDF	0.00%	0.00%	0.00%	0.00%
ARZTY	19.40%	7.19%	2.36%	10.24%

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q3 2025	13.95	0.02	+6.1%	View
Q2 2025	12.61	0.00	+9.6%	View
Q1 2025	13.62	0.01	-45.5%	View
Q4 2024	12.75	0.01	-1.9%	View
Q3 2024	13.15	0.01	+0.4%	View

Integrated BioPharma Inc (INBP) Q3 2025 Earnings Report

Earnings Highlights

Integrated BioPharma Inc (INBP) QQ3 2025 Results Analysis — Modest Revenue Growth, Lean Operations, and Solid Liquidity in Packaged Foods

Executive Summary

Key Performance Indicators

Revenue

Gross Profit

Operating Income

Net Income

EPS

Revenue Trend

Margin Analysis

Key Insights

Financial Highlights

Income Statement

Key Financial Ratios

Net Income vs. Revenue

Expense Breakdown

Management Commentary

Forward Guidance

Competitive Position

Gross Profit Margin

Operating Profit Margin

Return on Equity

P/E Ratio Comparison

Investment Outlook

Key Investment Factors

Growth Potential

Profitability Risk

Financial Position

SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Historical Earnings Comparison

Integrated BioPharma Inc (INBP) Q3 2025 Earnings Report

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue

Gross Profit

Operating Income

Net Income

EPS

Revenue Trend

Margin Analysis

Key Insights

Financial Highlights

Income Statement

Key Financial Ratios

Net Income vs. Revenue

Expense Breakdown

Management Commentary

Forward Guidance

Competitive Position

Gross Profit Margin

Operating Profit Margin

Return on Equity

P/E Ratio Comparison

Investment Outlook

Key Investment Factors

Growth Potential

Profitability Risk

Financial Position

SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Historical Earnings Comparison

More INBP Quarterly Reports

INBP

INBP

INBP

INBP

Q3 2025 Reports in Consumer Defensive Sector

Related Financial Data

Sector Analysis: Consumer Defensive

INBP Full Profile

INBP Financial Statements

Earnings Calendar